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SUMMARY 
Intracellular signalling pathways are reliant on protein phosphorylation events that are 
controlled by a balance of kinase and phosphatase activity. Although kinases have been 
extensively studied, the role of phosphatases in controlling specific cell signalling 
pathways has been less so. Leukocyte common antigen-related protein (LAR) is a member 
of the LAR subfamily of receptor-like protein tyrosine phosphatases (RPTPs). LAR is 
known to regulate the activity of a number of receptor tyrosine kinases, including platelet-
derived growth factor receptor (PDGFR). To gain insight into the signalling pathways 
regulated by LAR, including those that are PDGF-dependent, we have carried out the first 
systematic analysis of LAR-regulated signal transduction using SILAC-based quantitative 
proteomic and phosphoproteomic techniques. We have analysed differential 
phosphorylation between wild-type mouse embryo fibroblasts (MEFs) and MEFs in which 
the LAR cytoplasmic phosphatase domains had been deleted (LARΔP), and found a 
significant change in abundance of phosphorylation on 270 phosphosites from 205 proteins 
due to the absence of the phosphatase domains of LAR. Further investigation of specific 
LAR-dependent phosphorylation sites and enriched biological processes reveal that LAR 
phosphatase activity impacts on a variety of cellular processes, most notably regulation of 
the actin cytoskeleton. Analysis of putative upstream kinases that may play an intermediary 
role between LAR and the identified LAR-dependent phosphorylation events has revealed 
a role for LAR in regulating mTOR and JNK signalling.  
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INTRODUCTION 
Phosphorylation is a key post-translational modification (PTM) involved in the 
regulation of cell signalling. Control of phosphorylation is vital in maintaining normal 
biological processes, and dysregulation is implicated in many diseases. Kinases and 
phosphatases have opposing roles in modulating levels of phosphorylation, acting in a 
coordinated manner within cells to maintain cellular homeostasis via their regulation 
of cell signalling pathways. Historically phosphatases were viewed as being 
promiscuous enzymes whose role was simply to dephosphorylate their substrates in 
order to terminate signal transduction pathways. It is now evident that phosphatases 
display selectivity and are not simply ‘off switches’ but can contribute to both 
deactivation and activation of signalling pathways (1). Whilst the role of kinases has 
been extensively studied, much less is known about phosphatases and their specific 
contributions to cell signalling.  
 
Leukocyte common antigen-related protein (LAR) belongs to the LAR subfamily of 
receptor-like protein tyrosine phosphatases (RPTPs). It is composed of an 
extracellular domain containing three immunoglobulin domains (Ig), a fibronectin 
type III domain (FNIII), and cytoplasmic domains - D1 and D2 that are essential for 
phosphatase activity (2-4). LAR is widely expressed in a variety of cell types, such as 
neuronal cells, epithelial cells and fibroblasts (5). Several disorders are associated 
with LAR including defective development of mammary glands, abnormal neuronal 
development and function, diabetes and cancer (6, 7). Signal transduction regulated 
by LAR has thus far predominantly been studied in neuronal cells, where it 
participates in axonal outgrowth, nerve regeneration and orchestration of synapse 
development (6, 8). LAR regulates tyrosine kinase receptor growth factor signalling 
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by either dephosphorylating negative regulatory tyrosine residues to enhance receptor 
activation (9), or by dephosphorylating activating tyrosine residues to deactivate the 
receptor (10, 11). LAR localises to integrin-based focal adhesion complexes (12) and 
adherens junctions (13).  
 
Platelet-derived growth factor (PDGF) signalling is involved in many cellular 
processes such as cell growth, survival and motility (14). Overexpression of the 
PDGF receptor is associated with diseases such as atherosclerosis and cancer, 
signifying it as a target for therapeutic interventions (15-17). PDGF isoforms act as 
dimers composed of interacting A, B, C and D polypeptide chains. These can be 
homodimeric or heterodimeric isoforms that can interact with PDGF α and PDGF 𝛽 
receptors leading to receptor dimerization and activation of kinase activity via 
autophosphorylation (18). This results in the recruitment and activation of signalling 
pathways that culminate in transcriptional responses and the promotion of cell 
proliferation and survival (18, 19). 
 
Phosphatases are generally considered as negative regulators of signalling pathways. 
A number of protein tyrosine phosphatases (PTPs) have been reported to 
dephosphorylate tyrosine residues (Tyr) on PDGFR𝛽 thereby deactivating the 
receptor and inhibiting downstream signalling. For example, dephosphorylation of 
Tyr857 on PDGFR𝛽 by low molecular weight protein tyrosine phosphatase (LMW-
PTP) inhibits the receptor kinase activity and subsequent downstream signalling via 
PI-3 kinase (20). T-cell protein tyrosine phosphatase (TC-PTP) has been shown to 
inhibit binding of phospholipase C γ1 (PLC γ1) through dephosphorylation of 
Tyr1021 that results in altered cell migration in response to PDGF (21). SHP-2 can 
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inhibit binding of Ras-GAP to PDGFR𝛽 by dephosphorylation of PDGFR𝛽 Tyr771, 
which results in enhanced activity of the Ras signalling pathway (22). By contrast, 
LAR promotes PDGF signalling by inhibiting activity of the cytoplasmic tyrosine 
kinase, c-Abl (23). In the absence of LAR phosphatase activity c-Abl inhibits 
PDGFR𝛽 signalling by phosphorylating and inhibiting the receptor (23). 
 
In this study, we set out to gain insight into the landscape of cell signalling events 
regulated by LAR. In the first systematic analysis of LAR-regulated signal 
transduction we have used stable isotope labelling by amino acids in cell culture 
(SILAC) (24, 25) to analyse differential phosphorylation in wild-type (WT) mouse 
embryo fibroblasts (MEFs) and MEFs in which the LAR cytoplasmic phosphatase 
domains had been deleted (LARΔP) (26). Whilst LAR is known to promote PDGFR 
activation in fibroblasts (23), the signalling consequences of this regulation have not 
been fully studied, thus we carried out these studies in the absence and presence of 
PDGF. We identified 270 LAR-dependent phosphorylation events on 205 proteins, 
including known LAR interactors, kinases, guanine nucleotide exchange factors 
(GEFs) and GTPase activating proteins (GAPs). Subsequent functional classification 
revealed an enrichment of LAR-mediated phosphorylation events on proteins 
involved in cytoskeletal organisation. Further kinase prediction analysis revealed a 
role for LAR in regulating both mTOR and JNK signalling pathways, both of which 
play a role in regulation of the actin cytoskeleton.  
 
These results significantly expand our understanding of signalling events downstream 
of LAR. This approach has enabled us to identify LAR-dependent changes in 
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phosphorylation within the entire signalling network, highlighting the role of LAR as 
a key regulator of growth factor-dependent cell signalling pathways. 
 
EXPERIMENTAL PROCEDURES 
Reagents and antibodies 
Antibodies were purchased from Cell Signalling Technologies (SAPK/JNK, 
SAPK/JNK Thr183/Tyr185, mTOR, mTOR Ser2448, P70S6K Thr389, c-Jun, c-Jun 
Ser63, MKK7, MKK7 Ser271/Thr275), Santa Cruz (ERK1/2 and ERK 
Thr202/Tyr204), and Sigma (Flag). Recombinant human PDGF-BB was obtained 
from Cell Signalling Technologies.  Rabbit polyclonal Alix has been previously 
described (27). The secondary goat anti-mouse and goat anti-rabbit IgG IRDye 
conjugated antibodies were from LI-COR Biosciences. 
 
Cell culture  
Mouse embryonic fibroblasts (MEFs) from mice where the LAR phosphatase 
domains had been deleted (LARΔP) and from littermate wild-type (WT) (26), were 
used in the study (both cell types are kind gifts from Wiljan J.A.J. Hendriks, 
Radbound University Medical Center, Nijmegen, Netherlands). Cells were grown in 
DMEM supplemented with 10 % foetal bovine serum (FBS), 100 U/mL penicillin, 0.1 
mg/mL streptomycin, and 250 µg/mL amphotericin B. For SILAC labelling, cells 
were cultured in SILAC DMEM (Thermo Fisher Scientific) supplemented with either 
“light” isotopically normal L-Lysine and L-Arginine (R0K0) (Sigma), “medium” 13C6 
L-Arginine and 4,4,5,5-D4 L-Lysine (R6K4), or “heavy” 13C6 15N4 L-Arginine and 
13C6 15N2 L-Lysine (R10K8) (Goss Scientific), with 0.5 mg/mL proline (Sigma), 0.1 
mg/mL streptomycin, 100 U/mL penicillin, 250 µg/mL amphotericin B and 10 % v/v 
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dialysed fetal bovine serum (Labtech International). Cells were grown in SILAC 
media for 7 doubling times before being analysed for incorporation efficiency of the 
SILAC amino acids (see supplemental Figure S1).  
 
Transfection 
The FLAG-LAR expression vector was kindly provided by Ruey-Hwa Chen 
(National Taiwan University, Taipei, Taiwan). LARΔP cells were transfected using 
Lipofectamine 2000 (Thermo Fisher Scientific) according to manufacturer’s 
instructions. 
 
Cell stimulation, cell lysis and immunoblotting 
Cells were serum starved for 16 hours prior to stimulation with 20 ng/mL PDGF-BB 
for the indicated times. Treated cells were placed on ice and washed twice with ice-
cold phosphate buffered saline (PBS). Cells were then lysed with lysis buffer (20 mM 
Tris–HCl, pH 7.5, 0.5 % Triton X-100, 0.5 % deoxycholate, 150 mM NaCl, 10 mM 
EDTA, 0.5 mM Na3VO4 and 1 % Trasylol) for 15 minutes on ice. Lysed cells were 
centrifuged at 15000 x g for 15 minutes at 4 ˚C and the supernatant (WCL) was 
collected. Protein concentrations were determined using the BCA protein assay 
(Thermo Scientific) as per the manufacturer’s instructions. An equal volume of 2X 
sample buffer (1.0 M Tris-HCl pH 8.8, 0.5 % Bromophenol blue, 43.5 % glycerol, 10 
% SDS, 1.3 % β-mercaptoethanol) was added to the WCL, and the sample was boiled 
at 95 ˚C for 6 minutes. Samples were run on SDS-PAGE gels and transferred to 
nitrocellulose membranes. The membranes were blocked with 5 % bovine serum 
albumin (BSA) (Sigma Aldrich) at room temperature for one hour and incubated in 5 
% BSA in TBS-T (20 mM Tris–HCl, pH 7.5, 0.1 % Tween 20, 150 mM NaCl) 
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containing primary antibody overnight at 4 ˚C. Following 3 x 10 minute washes in 
TBS-T, the membrane was incubated in TBS-T containing IRDye conjugated 
secondary antibody (LI-COR Biosciences) for 1 hour at room temperature. The 
membranes were washed again as above and proteins were visualized using 
fluorescence detection on the Odyssey Infrared Imaging System (LI-COR 
Biosciences). Following quantitation of immunoblots (n=3) statistical analysis was 
performed using a two-way ANOVA, Sidak’s multiple comparison test. 
 
Trypsin digestion, sample fractionation and phosphopeptide enrichment of samples 
For the proteome analysis, 5 µg of “light”, “medium” and “heavy” lysates were 
mixed, run on a 10 % SDS-PAGE gel, and Coomassie stained. Each lane was cut into 
10 bands. In-gel digestion using Trypsin Gold (Promega) was carried out as 
previously described (28). For the phosphoproteome analysis, 10 mg of “light”, 
“medium” and “heavy” lysates were pooled prior to trypsin digestion. Proteins were 
reduced with 8 mM DTT, alkylated with 20 mM iodoacetamide in 50 mM ammonium 
bicarbonate and digested with Trypsin Gold (1:100 enzyme:protein ratio) at 37 ˚C 
overnight. Digested samples were acidified by addition of 0.5 % TFA. Peptides were 
desalted using Sep-Pak C18 Cartridges (Waters, Milford, MA) according to 
manufacturer’s instructions. Desalted and dried peptides were resuspended in 100 µL 
mobile phase A (10 mM KH3PO4, 20 % acetonitrile, pH 3) and loaded onto a 100 × 
4.6 mm polysulfoethyl A column (5 µm particle size, 200 nm pore size, PolyLC). 
Separation used a gradient elution profile that started with 100 % mobile phase A, 
increased from 0 to 50 % mobile phase B (10 mM KH3PO4, 20 % acetonitrile, 500 
mM KCl, pH 3) over 30 min, increased to 100 % B over 5 min, and then returned to 
100 % A. Each of the 20 resulting fractions was desalted using a C8 macrotrap 
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cartridge (Michrom BioResources) according to manufacturer’s instructions. 
Phosphopeptides were enriched using TiO2 tips (TitansphereTM Phos-TiO kit, GL 
Sciences). Tips were washed in buffer A (0.5 % (v/v) TFA, 80 % (v/v) ACN) and 
equilibrated in buffer B (0.38 % (v/v) TFA, 60 % (v/v) ACN, 25 % (v/v) lactic acid).  
Phosphopeptides were resuspended in buffer B and loaded onto the tips, washed once 
in buffer B and twice in buffer A before being eluted sequentially in 5 % ammonia 
solution followed by 5 % pyrrolidine. Phosphopeptide-enriched samples were 
desalted on reverse-phase C18 ZipTips (Millipore). Peptides were eluted in 50 % 
(v/v) ACN, 0.1 % (v/v) formic acid (FA), dried to completion and resuspended in 0.1 
% FA. All resulting peptide mixtures were analysed in duplicate by liquid 
chromatography tandem mass spectrometry (LC-MS/MS).  
 
Mass spectrometry  
On-line liquid chromatography was performed by use of a Dionex Ultimate 3000 
NSLC system (Thermo Fisher Scientific). Peptides were loaded onto an Acclaim 
PepMap 100 C18 resolving column (15 cm length; 75 µm internal diameter; LC 
Packings, USA) and separated over a 30 minute gradient from 3.2 % to 44 % 
acetonitrile (Baker, Holland). Peptides were eluted directly (350 nL/min) via a 
Triversa nanospray source (Advion Biosciences, NY, USA) into a LTQ Orbitrap Elite 
mass spectrometer (Thermo Fisher Scientific). The mass spectrometer alternated 
between a full FT-MS scan (m/z 380-1600) and subsequent CID MS/MS scans of the 
seven most abundant ions. Survey scans were acquired in the Orbitrap cell with a 
resolution of 60,000 at m/z 200. Precursor ions were isolated and subjected to CID in 
the linear ion trap. Isolation width was 2 Th and only multiply-charged precursor ions 
were selected for MS/MS. The MS1 maximum ion inject time was 1000 ms with an 
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AGC target of 1e6 charges. The MS2 ion inject time was 50ms with an AGC target of 
2e5 charges. Dynamic exclusion was utilised, fragmented ions were excluded for 60 
seconds with an exclusion list size of 500. CID was performed with helium gas at a 
normalised collision energy of 35 %. Precursor ions were activated for 10 ms. Data 
acquisition was controlled by Xcalibur 3.0.63 software. 
 
Identification and quantification of peptide and proteins 
Mass spectra were processed using the MaxQuant software (version 1.5.3.8) (29). 
Data were searched, using the Andromeda search engine within MaxQuant (30), 
against the mouse Swiss-Prot database (downloaded 6.10.15). The mouse database 
contained 16,719 reviewed protein entries. The search parameters were: minimum 
peptide length 7, peptide tolerance 20 ppm (first search) and 6 ppm (second search), 
mass tolerance 0.5 Da, cleavage enzyme trypsin/P, and 2 missed cleavages were 
allowed. Carbamidomethyl (C) was set as a fixed modification. Oxidation (M), 
acetylation (Protein N-term), and phospho (STY) were set as variable modifications. 
The appropriate SILAC labels were selected and the maximum labelled amino acids 
was set to 3. All experiments were filtered to have a peptide and protein false-
discovery rate (FDR) below 1 % and the match between runs featured was enabled. 
All raw files from both the phosphoproteome and proteome pipeline were analysed 
together in MaxQuant. Within the MaxQuant output, phosphorylation sites were 
considered to be localised correctly if the localisation probability was at least 0.75 (75 
%) and the score difference at least 5. Bioinformatics analysis was performed in the 
Perseus software environment, which is part of MaxQuant (Perseus version 1.5.0.15; 
www.perseus.framework.org). Significance testing was carried out using a Student’s 
t-test on log 2 transformed ratios and controlled with a Benjamini-Hochberg FDR 
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threshold of 0.05. Peptides quantified in three or more experimental repeats were 
deemed significantly changed and regulated by LAR phosphatase activity if they had 
a p-value of < 0.05 and a ratio of < 0.667 or > 1.5 (at least a 1.5-fold change in 
abundance). 
 
The mass spectrometry proteomics data, including the MaxQuant output, have been 
deposited to the ProteomeXchange Consortium via the PRIDE partner repository with 
the dataset identifier PXD002545 (31). 
 
Cluster analysis, GO analysis, and Kinase motif analysis 
GProX software (32) was used to perform clustering of log2 transformed ratios from 
the MaxQuant output. Unsupervised fuzzy c-means clustering was used with an upper 
regulation threshold of 1 and a lower regulation threshold of -1. Overrepresentation of 
GO terms in the clusters was performed within GProX using a binomial statistical test 
with a Benjamini-Hochberg p-value adjustment, a p-value threshold of 0.05, and a 
minimum occurrence of 2. DAVID (Database for Annotation, Visualization and 
Integrated Discovery) (33) was used to identify over-represented GO terms in the 
phosphoproteome dataset. The background list comprised of all of the proteins 
identified across our experiments. The threshold count and EASE score were set to 2 
and 0.05 respectively. Phosphopeptides containing well localised phosphosites were 
analysed for predicted kinase motifs using GPS (34) with a high stringency setting. 
Protein network visualisation was performed using Cytoscape (35) with WordCloud 
plugin (36).  
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RESULTS  
 
Absence of LAR phosphatase activity leads to alterations in the global phosphoproteome 
and proteome 
Our aim was to gain insight into the protein signalling networks downstream of LAR. We 
utilised SILAC (24, 25) to quantitatively compare levels of protein expression (proteome 
analysis) and phosphorylation (phosphoproteome analysis) in PDGF-stimulated wild-type 
(WT) and LARΔP (lacking cytoplasmic phosphatase domains) MEFs. Three populations of 
WT and LARΔP cells were SILAC-labelled by culturing them in ‘Light’ R0K0, ‘Medium’ 
R6K4, or ‘Heavy’ R10K8 SILAC media. Cells were left untreated or stimulated with PDGF-
BB for 7 minutes as indicated in Figure 1A. Within the phosphoproteome dataset, 2559 
unique phosphosites from 1311 proteins were identified with high localisation scores 
(localisation probability > 0.75; score difference > 5) in one or more experimental replicates. 
These phosphosites were comprised of 2125 (83 %) serine, 260 (10 %) threonine and 174 (7 
%) tyrosine phosphorylation sites. Of these, 266 (10 %) are not listed in PhosphoSitePlus (37) 
and are considered novel.  
 
To compare the phosphoproteome of PDGF stimulated WT and LARΔP cells four biological 
replicates, including a label swap control, were incorporated into the experimental design 
(Figure 1A).  The overlap between the four biological replicates is shown in supplemental 
Figure S2A: 54 % of the phosphopeptides were identified in 2 or more replicates, and 27 % 
were identified in 3 or more replicates. The Pearson’s correlation coefficient for the peptide 
ratios measured across the four biological replicates, including the label swap experiment, 
ranged from 0.64 - 0.86 indicating good biological reproducibility (supplemental Figure 
S2B). In cells lacking LAR phosphatase activity, a total of 270 phosphopeptides from 205 
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proteins showed a significant change in abundance (p < 0.05; > 1.5-fold change) (Figure 1B; 
supplemental Table S1). Of these, 255 (95 %) contained serine phosphorylation sites, 9 (3 
%) threonine, and 6 (2 %) tyrosine. A total of 103 phosphosites were up-regulated and 167 
down-regulated. Within our phosphoproteome dataset we identified serine, threonine and 
tyrosine phosphorylation events mediated by LAR allowing us to gain an understanding of 
the global signalling landscape. LAR could contribute to the regulation of phosphorylation on 
these sites via modulation of the activity of specific kinases and phosphatases, or in the case 
of tyrosine, via direct dephosphorylation, given that LAR is a tyrosine phosphatase.  
 
These LAR-dependent changes in phosphopeptide abundance could be due to alterations in 
regulation of specific phosphorylation events or changes in protein abundance, hence our 
combined proteomic and phosphoproteomic approach. Within the proteomic dataset 
(comparing PDGF treated WT cells and LARΔP cells) a total of 2939 proteins were 
identified; 1150 with associated quantitation data in two or more biological replicates. Of 
these, 147 proteins (47 up-regulated; 100 down-regulated) showed a significant change (p < 
0.05; > 1.5-fold change) in abundance in the LARΔP cells compared to the WT cells (Figure 
1C; supplemental Table S2). This is a significant finding as 13 % of the quantified proteome 
was changed due to the absence of LAR phosphatase activity, suggesting that LAR may be 
involved in regulating protein turnover. Merging the phosphoproteome and proteome datasets 
resulted in a measure of corresponding protein abundance for 23 % of the quantified 
phosphorylation sites. Of the 270 LAR-dependent phosphorylation events, 11% changed 
significantly at the level of the proteome indicating regulation at the protein level rather than 
the peptide level.  
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Tyrosine phosphorylation regulated by LAR 
Considering potential direct LAR substrates, a loss of LAR phosphatase activity would lead 
to an increase in tyrosine phosphorylation of these proteins, hence we looked for tyrosine 
phosphorylated peptides within the dataset that increased in LAR∆P cells. Only one tyrosine 
phosphorylated peptide, belonging to the protein Lcp2 (SLP76), increased in abundance in 
the absence of LAR activity (LAR∆P cells) (supplemental Table S1). SLP76 is an adaptor 
protein, mostly studied in T cells, that relays signals from activated receptors to the 
cytoskeleton (38). We have identified an increase in Tyr465 phosphorylation which is a 
tyrosine residue located in the C-terminal SH2 domain of SLP76. The remainder of the 
tyrosine phosphopeptides decrease in abundance in LAR∆P cells, which suggests that the 
regulation of phosphorylation on these sites is via an indirect LAR-regulated mechanism. 
  
Biological processes regulated by LAR 
Gene Ontology (GO) analysis of the phosphoproteins regulated by LAR revealed a number of 
enriched GO biological processes, molecular functions and cellular components. The most 
significantly enriched terms are shown in Figures 2A, B and C (for full DAVID output see 
supplemental Table S3). The dominant enriched GO terms were associated with cytoskeletal 
organisation and cell adhesion. LAR has been shown to regulate the cytoskeleton in 
conjunction with TRIO, a guanine nucleotide exchange factor for small GTPases (39). Here 
we have identified a 3-fold increase in the phosphorylation of TRIO on Ser2458 and Ser2462 
in LARΔP cells, indicating that LAR dependent signalling networks are regulating its 
phosphorylation status. Despite this link to cytoskeletal organisation, the extent of the LAR-
dependent cytoskeletal regulatory network has not been previously studied. It is evident from 
our phosphoproteome dataset that a large number of cytoskeletal proteins are dependent upon 
LAR phosphatase activity to regulate their phosphorylation (Figure 2D). LAR has also been 
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shown to interact with cadherin, β-catenin, and plakoglobin to regulate adherens junctions 
and desmosomes (40-42). Here, we have identified specific LAR-dependent phosphorylation 
sites on these proteins and discovered additional LAR regulated cell junction proteins 
(Figure 2D). In LARΔP cells we have identified a decrease in phosphorylation on cadherin-
11 (Ser714), α-catenin (Ser641), β-catenin (Ser191; Ser675), δ-catenin (Ser864), and 
plakoglobin (Ser665), all proteins present at sites of cell-cell adhesion. β-catenin is a reported 
substrate for LAR, and tyrosine dephosphorylation has been linked to inhibition of epithelial 
cell migration (43). Here, we have not identified specific tyrosine phosphorylation sites on β-
catenin that may be directly dephosphorylated by LAR, but instead we identified two serine 
residues with altered phosphorylation. Phosphorylation of one of these, Ser191, by JNK2 has 
been shown to be essential for nuclear accumulation of β-catenin in response to Wnt (44). It 
is possible that LAR is capable of regulating β-catenin phosphorylation indirectly by 
regulating the activity of kinases that phosphorylate β-catenin, such as JNK2, as well as 
directly by dephosphorylating specific tyrosine residues (43). In addition, we have evidence 
that LAR also regulates tight junctions with phosphorylation of two key proteins, ZO-1 
(Tjp1) and ZO-2 (Tjp2), decreased in LARΔP cells (ZO-1 Ser1614; ZO-2 Ser107; Ser239; 
Ser1136).  
 
LAR-regulated phosphorylation events downstream of PDGF 
In order to identify differential changes in abundance within the phosphoproteome dataset, 
phosphopeptides were clustered according to their response to PDGF stimulation versus 
unstimulated cells. The comparison of PDGF stimulated WT and LARΔP cells versus 
unstimulated WT cells allowed the evaluation of the comparative endpoint of phosphopeptide 
abundance. This is the phosphorylation signal that the cells would ultimately respond to in 
the presence of PDGF. This may be due to a differential response to PDGF or constitutive 
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down- or up-regulation in unstimulated LARΔP cells, hence we also included a comparison 
of PDGF stimulated LARΔP cells versus unstimulated LARΔP cells. Our experimental 
design included three biological replicates for the ratio between PDGF treated and 
unstimulated WT cells, and two biological replicates for the ratios between PDGF treated 
LARΔP cells and unstimulated WT or LARΔP cells (Figure 1A). We obtained ratios for 375 
peptides, each of which had been quantified in two biological replicates. Six clusters were 
identified (Figure 3A and supplemental Table S4). Clusters 2, 3, 4 and 6 contained those 
phosphopeptides that, in the presence of PDGF, showed a LAR phosphatase-dependent 
alteration in relative abundance when compared to basal levels in WT cells. This is not true 
for those phosphopeptides in clusters 1 and 5 where similar levels were observed in both 
PDGF stimulated WT and LARΔP cells when compared to unstimulated WT cells. 
Phosphopeptides in clusters 2 and 3 exhibited similar fold changes in phosphopeptide 
abundance due to PDGF stimulation in both WT and LARΔP cells compared to their basal 
levels, however, the abundance in PDGF stimulated LARΔP cells compared to unstimulated 
WT cells was significantly different. This indicated that the absence of LAR phosphatase 
activity causes changes in basal levels of phosphorylation on these phosphoproteins. 
Phosphopeptides in clusters 4 and 6 have a similar fold change in LARΔP cells in response to 
PDGF, whether this is compared to unstimulated WT or LARΔP cells. However, the fold 
change is different to that observed in WT cells.   
 
Enrichment analysis for GO terms over-represented in each cluster showed a clear distinction 
between the biological roles regulated by these groups of phosphoproteins (supplemental 
Figure S3; supplemental Table S4). This is highlighted in Figure 3B which is focused on 
Cellular Component GO Terms. There is a clear distinction between the discrete cellular 
components within which the differentially regulated phosphopeptides reside. The majority 
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of the enriched terms are cytoskeletal and vesicular compartments. With regards to PDGF 
stimulation, cluster 4 is perhaps the most interesting as these proteins contain phosphosites 
that are rapidly phosphorylated in response to PDGF; however, this is not the case when LAR 
phosphatase activity is reduced. These responses are not due to constitutive down-regulation 
in LARΔP cells.  One of the enriched components in this cluster is the late endosome 
compartment (GO:0005770), which contains a Rab7a peptide phosphorylated on Ser72. 
Phosphorylation of this residue on Rab7a plays a regulatory role in late endosome maturation 
(45) and our data revealed a 14-fold increase in response to PDGF in WT cells; however, this 
was reduced over two-fold in LARΔP cells (supplemental Table S4). Within cluster 4 there 
was also an enrichment of cytoskeletal proteins (GO:0005856) including Sorbs3 (vinexin), a 
protein involved in regulation of actin stress fibre formation (46), and Add3 (gamma-
adducin), a protein that promotes assembly of the spectrin-actin network which plays a role in 
regulating both adherens and tight junctions (47). We have identified phosphorylation events 
on both Sorbs3 and Add3 that are reduced by up to 3-fold in the absence of LAR activity, 
hence this activity is a requirement for PDGF-regulated phosphorylation of these proteins 
(supplemental Table S4). These data highlight the interplay between LAR and PDGF in 
regulation of the cytoskeleton and protein transport. 
 
Regulation of kinase activity by LAR  
LAR-dependent phosphorylation of several kinases has been identified (Figure 2D). These 
include Braf (B-Raf) and Mapk1 (ERK2), both members of the Ras-MAPK signalling 
pathway. An increase in B-Raf Ser484 and a decrease in ERK2 Tyr185 was observed in 
LARΔP cells. Phosphorylation of ERK1 and 2 on Thr183 and Tyr185 (Thr202/Tyr204 in 
human) occurs during MAPK signalling and activates the ERK kinases, which in turn can 
phosphorylate their many substrates. PDGF-dependent ERK1/2 phosphorylation at these 
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activating sites has previously been shown to be reduced in the absence of LAR phosphatase 
activity (23) and this was verified here. Analysis of PDGF-dependent ERK phosphorylation 
in WT and LARΔP cells confirms that ERK activity is significantly reduced in LARΔP cells 
treated with PDGF when compared to WT cells (Figures 4A and 4B). Re-expression of WT 
LAR in LARΔP cells increased ERK phosphorylation to levels resembling those observed in 
WT cells, confirming that LAR phosphatase activity is required for ERK activation (Figures 
4C and 4D). 
 
With an aim to delineate further signalling pathways regulated by LAR we sought to identify 
those kinases which may be responsible for inducing phosphorylation of substrates within our 
phosphoproteomic dataset. The kinase prediction tool GPS (34) was used to identify 
predicted kinases upstream of substrate motifs containing a phosphorylation site showing 
differential abundance between WT and LARΔP (270 phosphopeptides). Our proteome 
dataset allowed the identification of instances where phosphopeptide abundance was a result 
of proteome regulation rather than control of specific phosphorylation sites by regulatory 
kinases and phosphatases. In order to control for these effects, any proteins found to have a 
similar fold change in expression to the change in phosphopeptide abundance were not 
included in our analysis. Of the remaining 240 LAR-regulated phosphorylation sites, 223 
were identified as putative substrates for a particular kinase (supplemental Table S5). 
Members of the CMGC family (includes Cyclin-dependent kinases, Mitogen-activated 
protein kinases, Glycogen synthase kinases and CDK-like kinases) were predicted to 
phosphorylate the majority of sites (Figure 5). The most predominant predicted kinase 
subfamily was the CMGC/CDK family followed by the CMGC/MAPK subfamily, including 
ERK, JNK, and p38 kinases. Other predominant kinases were MAPKAPK and mTOR 
(Figure 5).  
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LAR regulates mTOR signalling  
Our kinase prediction analysis revealed mTOR as a prominent node of regulation (Figure 5). 
The mTOR signalling pathway is known to regulate protein synthesis via the mTORC1 
complex and cytoskeletal organisation via the mTORC2 complex (48). Considering the 
significant changes in protein abundance in LARΔP cells and also the number of LAR-
regulated cytoskeletal proteins identified it was hypothesised that LAR may be regulating the 
mTOR pathway. In order to further analyse the role of LAR in regulating the activity of 
mTOR we used antibodies recognising Ser2448 phosphorylated mTOR and Thr389 
phosphorylated P70S6 kinase, both of which are indicators of active mTOR signalling. In 
WT cells, phosphorylation of mTOR on Ser2448 increased following stimulation with PDGF 
(Figures 4A and 4B). However, the absence of LAR phosphatase activity in LARΔP cells 
resulted in a significant decrease in PDGF-dependent phosphorylation of this residue 
establishing a role for LAR in mTOR signalling (Figures 4A and 4B). Analysis of P70S6 
kinase Thr389 phosphorylation revealed a similar response to PDGF to that seen with mTOR 
Ser2448 in WT cells and reduced phosphorylation in LARΔP cells (Figures 4A and 4C). Re-
expression of WT LAR in LARΔP cells resulted in an increase in mTOR Ser2448 
phosphorylation to levels resembling those observed in WT cells (Figure 4D and 4E). Taken 
together, these results confirm a novel role for LAR phosphatase in the regulation of mTOR 
signalling.   
 
JNK is a key node of kinase regulation by LAR 
JNK kinases are involved in regulation of the actin cytoskeleton, a role also played by LAR. 
Predicted substrates for JNK kinases were found enriched within our phosphoproteomic 
dataset (Figure 5). Using GPS (34), predicted JNK targets identified in our dataset of LAR-
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dependent phosphosites included: Eps8, a highly phosphorylated signalling adaptor protein 
that regulates actin dynamics and architecture (49-53); Stathmin1 and Stathmin2, both 
involved in microtubule disassembly (54); Tjp1, involved in tight junction assembly (55); and 
Tenc1 (Tns2), a focal adhesion protein that binds actin filaments (56). JNK is known to 
phosphorylate Ser62 of Stathmin 2 (57) and phosphorylation of this residue was significantly 
reduced in LARΔP cells compared to WT. These data prompted us to investigate whether 
LAR phosphatase regulates JNK phosphorylation. In the absence of LAR phosphatase 
activity, we observed significantly reduced JNK activity upon stimulation with PDGF 
(Figures 7A and 7B).  Consistent with this, we also observed a significant decrease in 
activity of MKK7, an upstream kinase known to activate JNK (Figures 7A and 7C), and also 
a JNK downstream effector, c-Jun (Figure 7A and 7D), in LARΔP cells. Re-expression of 
WT LAR in LARΔP cells restored JNK phosphorylation (Figures 7E and 7F) demonstrating 
that LAR phosphatase domains are required for regulation of JNK activity. These data show 
LAR plays a role in regulating PDGF-mediated activation of the JNK signalling pathway.   
 
DISCUSSION 
Phosphorylation events are crucial for the regulation of cell signalling networks and, 
consequently, the cells response to a biological outcome. The regulatory role of kinases in 
specific cell signalling pathways has been long established. In more recent years it has been 
realised that phosphatases can be viewed in a similar manner and can regulate specific cell 
signalling events rather than acting as generic dephosphorylation enzymes as was once 
thought (1). The breadth of cell signalling pathways regulated by LAR has not previously 
been investigated. Using combined global quantitative phosphoproteomics and proteomics 
we have provided a comprehensive analysis of signalling events regulated by LAR 
phosphatase. The phosphorylation of 270 sites on 205 proteins was significantly up or down-
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regulated in LARΔP cells compared to WT cells. Our data establish that LAR phosphatase 
activity is essential for the regulation of many phosphorylation events within the cell that 
impact on a variety of cellular processes, particularly regulation of the cytoskeleton and cell-
cell interactions. Our dataset significantly expands the number of proteins regulated by LAR 
that are involved in these biological functions, and identifies specific regulatory phosphosites 
for future scrutiny. It is likely that LAR regulates phosphorylation via a number of 
mechanisms; via direct dephosphorylation, via regulation of activity of other phosphatases or 
kinases that can directly modulate the specific site, or via alterations in protein abundance.  
 
As well as regulation at the phosphoproteome level, the absence of LAR also caused 
considerable changes to the identified proteome. These results highlight a possible role for 
LAR phosphatase activity in maintaining levels of proteins within the cell, either via 
regulation of protein degradation or protein synthesis. We have evidence that LAR may be 
regulating both processes. Protein degradation is controlled via two major pathways: 
lysosomal proteolysis and the ubiquitin-proteasome pathway. A number of proteins with roles 
in these two pathways have significant changes in phosphorylation levels due to the inactivity 
of LAR. The phosphorylation of Ser72 on Rab7a, a small GTPase, was decreased in LARΔP 
cells. Dephosphorylation of this residue is necessary for late endosome maturation in 
preparation for lysosomal fusion and protein degradation (45). This is one example of LAR-
dependent regulation of a serine residue that is likely to occur indirectly via modulation of the 
activity of critical serine/threonine kinases or phosphatases upstream of Rab7a 
phosphorylation. Evidence for LARs involvement in protein ubiquitination is the 
identification of LAR-regulated phosphorylation sites on three E3 ubiquitin-protein ligases: 
Rffl (Ser254), Rlim (Ser229), and Dtx3l (Ser9). It is possible that the ubiquitin ligase activity 
of these proteins is regulated via these phosphorylation events. We have also identified LAR 
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as a regulator of mTOR signalling. mTOR is a serine/threonine protein kinase that regulates 
numerous cellular functions including protein synthesis and consequently, cell growth (58). 
Additionally, LAR-regulated phosphoproteins include those involved in translation of mRNA 
and protein synthesis. Hence, LAR may contribute to the maintenance of protein levels via 
the regulation of protein synthesis and mTOR signalling.  
 
Within the dataset are TRIO, and β-catenin, proteins known to interact with, and in the case 
of β-catenin be a substrate for LAR (13, 39, 43, 59-61). TRIO is a multi-domain protein that 
acts as a guanine-nucleotide exchange factor for Rac and Rho small GTPases (39) and β-
catenin an important protein involved in regulation of cell-cell junctions (62). In addition to 
localising LAR-regulated sites of phosphorylation on these proteins, we have also expanded 
the protein networks around these two proteins that also contain LAR-regulated phosphosites. 
For each of these proteins we identified LAR-mediated changes in serine phosphorylation 
which could result from an alteration in activity of a serine/threonine kinase or a 
serine/threonine phosphatase. These proteins may need to be localised in the vicinity of LAR 
via a direct interaction with TRIO or β-catenin in order to be regulated by these intermediate 
regulatory kinases or phosphatases.  
 
Also within our dataset are IRS1 and IRS2, adaptor proteins that bind to the insulin receptor 
and regulate insulin sensitivity (63). Both proteins are reported to interact with LAR (59, 60). 
LAR is known to regulate insulin dependent signalling, however, there is some debate in the 
literature as to whether this is due to direct dephosphorylation of the insulin receptor or a 
consequence of regulation of the pathway further downstream of the receptor (64, 65). IRS1 
has been reported to be direct substrate for LAR, however, there is some controversy over 
whether this is the case (64, 65). Despite evidence that serine and threonine phosphorylation 
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of IRS1 and IRS2 is important for regulation of insulin sensitivity (63) previous work has 
concentrated on identifying LAR-dependent tyrosine phosphorylation of IRS proteins. To 
date there has been no analysis of indirect, LAR-mediated, phosphorylation events on IRS1 
or IRS2 that contribute to modulation of the cells response to insulin. Here, we have 
identified a reduction in serine phosphorylation of both IRS1 (Ser265) and IRS2 (Ser362) in 
LARΔP cells. Significantly, both phosphorylation events are reported to be insulin dependent 
(63).  
 
Grouping the phosphopeptides according to their relative abundance in PDGF stimulated 
cells resulted in six distinct clusters. These clusters can be differentiated on their response to 
PDGF and also on their functional subclasses. There are three possible scenarios that may 
cause relative changes in abundance of the phosphopeptides between PDGF-stimulated 
LARΔP cells and unstimulated WT cells: (1) the levels of phosphorylation in unstimulated 
WT and LARΔP are similar, however, the response to PDGF is altered; (2) the basal level of 
phosphorylation of the specific residue in unstimulated LARΔP cells has changed, coupled 
with an absence of PDGF response or a similar fold response to wild-type cells; or (3) there is 
a change at the level of the proteome, i.e. a change in protein abundance in LARΔP cells. In 
each case the result would still be differential phosphorylation in PDGF-stimulated cells due 
to the absence of the phosphatase domains of LAR, which would ultimately lead to changes 
in signalling pathways reliant on the specific phosphorylation events. Using cluster analysis 
we have identified those phosphoproteins regulated by both LAR and PDGF, and these 
include Rab7a and a number of cytoskeletal proteins.  
 
c-Jun N-terminal kinase (JNK) is serine/threonine kinase which is activated by a broad range 
of external stimuli including PDGF, transforming growth factor-β, and environmental stress 
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(66). Signalling via JNK regulates cell migration and enhances chemotaxis in response to 
PDGF stimulation (67). Several strands of evidence supporting a role for LAR in regulating 
JNK signalling are present within our data. First, a member of the JNK signalling pathway, 
Zak, is present within the LAR-regulated phosphoproteomic dataset. JNK can be activated 
via phosphorylation of Thr183 and Tyr185 via the action of MKK4 and MKK7 kinases (68, 
69). Zak is a stress-activated kinase upstream of both MKK4 and MKK7 (70) and 
phosphorylation of Ser638 of Zak was increased 3.9-fold in LARΔP cells. This is the first 
strand of evidence that links LAR to JNK signalling. The second piece of evidence is the fact 
that we have identified specific JNK regulated phosphosites within the data that are regulated 
by LAR, including Ser191 of β-catenin, and Ser62 of Stathmin 2 (44, 57). In addition to this, 
using kinase motif predictions, we have identified JNK as a key node of regulation of a 
number of additional phosphosites within the LAR-regulated phosphoproteomics dataset. 
LAR-regulated PDGF-dependent phosphorylation of JNK on Thr183 and Tyr185 has been 
verified by western blotting. This demonstrates the strength of our approach in identifying 
novel signalling pathways regulated by LAR and has highlighted a novel role for LAR in 
regulating JNK signalling.  
 
CONCLUSIONS 
We have employed a global quantitative phosphoproteomics approach for the interrogation of 
LAR-mediated cell signalling events. We have focused on obtaining information pertaining 
to both direct and indirect phosphorylation events to increase our knowledge of the complete 
landscape of LAR-regulated signalling. The study has identified LAR as a regulator of key 
signalling pathways, including mTOR and JNK, and has significantly expanded the number 
of proteins regulated downstream of LAR phosphatase activity. 
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FIGURE LEGENDS 
 
Figure 1. Global phosphoproteomics and proteomics to measure contribution of 
phosphatase activity of LAR to PDGF signalling. (A) Schematic overview of experimental 
design. Volcano plots showing the magnitude (log2 fold-change) and significance (− log10 
Benjamini–Hochberg adjusted p-value) of differential phosphopeptide (B) and protein (C) 
abundance in PDGF-stumulated WT versus LARΔP cells. Significantly up-regulated 
phosphopeptides and proteins are marked in red (adjusted p-value < 0.05; > 1.5 fold-
change).  
 
Figure 2. LAR regulated distinct biological processes. Proteins containing the 270 LAR 
regulated phosphosites were analysed in DAVID to identify enriched GO Terms and 
keywords. The top (≤ 10) enriched categories for GO Biological Processes (A), GO 
Molecular Function (B) and GO Cellular Component (C) are plotted as bar charts.  (D) 
Proteins were clustered according to their keywords. Blue indicates that the protein 
contained a phosphosite(s) that was down-regulated in LARΔP cells and red indicates up-
regulation.  
 
Figure 3. Phosphorylation events in WT and LARΔP cells show clusters of regulation 
correlated to distinct biological processes. (A) GProX clustering of phosphopeptide 
abundance changes. Ratios of PDGF (7 minutes) stimulated WT and LARΔP cells over WT 
unstimulated cells and PDGF (7 minutes) stimulated LARΔP cells over LARΔP 
unstimulated cells were subjected to unsupervised clustering using the fuzzy c means 
alogrithm. The number of phosphopeptides in each cluster is indicated. (B) 
Overrepresentation of GO terms in the clusters was performed within GProX using a 
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binomial statistical test with a Benjamini-Hochberg p-value adjustment (p-value threshold 
0.05). Enriched categories for GO Cellular Components are represented as a heat map. 
 
Figure 4. LAR Regulates the ERK signalling pathway.  (A) WT and LARΔP cells were 
stimulated with 20 ng/mL PDGF for differing periods of time as indicated. Levels of ERK 
1/2 Thr202/Tyr204, total ERK and Alix in whole cell lysates were analysed by western 
blotting. (B) Western blots (n=3) were quantified and ratios of pERK to Alix were plotted 
over time (*** P < 0.001; * P < 0.05). (C) WT, LARΔP, and LARΔP cells transfected with 
Flag-WT-LAR were stimulated with 20 ng/mL PDGF for the indicated time periods. Levels 
of pERK 1/2, total ERK and Alix in whole cell lysates were analysed by western blotting. 
(D) Western blots (n=3) from the rescue experiments were quantified and ratios of pERK to 
Alix were plotted  (** P < 0.01). 
 
 
Figure 5. LAR Regulates Distinct Kinase Nodes. Phosphorylation sites regulated by LAR 
were searched using the kinase prediction tool GPS. All kinases predicted to phosphorylate 
at least five identified phosphorylation sites are displayed. Each node represents an 
individual kinase, and nodes are coloured according to kinase group (see key for details). An 
edge connecting two nodes indicates that the corresponding kinase groups were predicted to 
phosphorylate at least one common residue. Node size corresponds to the total number of 
LAR regulated phosphorylation sites that were predicted to be phosphorylated by the 
corresponding kinase. 
 
Figure 6. LAR Regulates the mTOR signalling pathway.  (A) WT and LARΔP cells were 
stimulated with 20 ng/mL PDGF for differing periods of time as indicated. Levels of mTOR 
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Ser2448, total mTOR, P70S6 Thr389, and Alix in whole cell lysates were analysed by 
western blotting. (B,C) Western blots (n=3) were quantified and ratios of phospho-proteins 
to Alix were plotted over time (*** P < 0.001; ** P < 0.01; * P < 0.05).  (D) WT, LARΔP, 
and LARΔP cells transfected with Flag-WT-LAR were stimulated with 20 ng/mL PDGF for 
the indicated time periods. Levels of mTOR Ser2448,  total mTOR, FLAG-LAR and Alix in 
whole cell lysates were analysed by western blotting.  (E) Western blots (n=3) from the 
rescue experiments were quantified and ratios of mTOR Ser2448 to Alix were plotted (*** P 
< 0.001; ** P < 0.01; * P < 0.05). 
 
 
Figure 7. LAR Regulates the JNK signalling pathway.  (A) WT and LARΔP cells were 
stimulated with 20 ng/mL PDGF for differing periods of time as indicated. Levels of JNK 
Thr183/Tyr185, total JNK, MKK7 Ser271/Thr275, total MKK7, c-Jun Ser63, c-Jun and Alix 
in whole cell lysates were analysed by western blotting. (B-D) Western blots (n=3) were 
quantified and ratios of phospho-protein to total protein were plotted over time (*** P < 
0.001; ** P < 0.01; * P < 0.05).  (E) WT, LARΔP, and LARΔP cells transfected with Flag-
WT-LAR were stimulated with 20 ng/mL PDGF for the indicated time periods. Levels of 
JNK Thr183/Tyr185, total JNK, Flag-LAR and Alix in whole cell lysates were analysed by 
western blotting.  (F) Western blots (n=3) from the rescue experiments were quantified and 
ratios of JNK Thr183/Tyr185 to total JNK were plotted (** P < 0.01). 
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